



# Do you have gastroparesis and diabetes?

Consider enrolling in the Envision 3D study, which is researching a study medication that may help.



## What are clinical research studies?

Clinical research studies help scientists and doctors explore whether a medication is safe and effective.

Before a doctor can prescribe a new medication, it must go through several phases of clinical research. Clinical research is only possible with the help of volunteers who participate in research studies. Participation is a choice, and volunteers may stop participating at any time.

For more information about the Envision 3D study, visit [gastroparesistrial.com](http://gastroparesistrial.com) or contact:



**envision<sup>3D</sup>**  
Study evaluating DeDomperidone in Diabetic gastroparesis patients

## What is the Envision 3D study?

Envision 3D is researching CIN-102, a study medication called deodomperidone. The Envision 3D study is for people who have gastroparesis with type 1 or type 2 diabetes.

## What is the study medication?

The study medication, called CIN-102 or deodomperidone, is a new form of domperidone. Domperidone is used in some countries for symptoms of diabetic gastroparesis as well as stomach-related issues such as nausea and vomiting. Unfortunately, domperidone can have serious side effects, so it is not approved for use in the United States but can be used under a special agreement between a physician and the Food and Drug Administration.

Deodomperidone (CIN-102) is made by slightly changing domperidone. It is expected to have similar benefits with fewer side effects. However, more research is needed.

## What can study participants expect?

Participation in the Envision 3D study lasts up to 18 weeks and includes the following steps:

-  Read and sign the Informed Consent Form (ICF)
-  Perform health assessments to confirm if you qualify for the study
-  Be assigned at random (like the flip of a coin) to receive either the study medication (CIN-102) or placebo (no active ingredients)
-  Take 2 capsules of the study medication or placebo twice per day for 12 weeks
-  Visit the study clinic about 8 times over 12 weeks for frequent health check-ups, medical care, and study health assessments
-  Visit the study clinic for follow-up health assessments, 1 week after your last dose

## Who can join the study?

You may be eligible to join if you meet the following criteria\*:

- Age 18 or older
- Diagnosed with type 1 or type 2 diabetes
- Diagnosed with gastroparesis, including gastrointestinal symptoms such as nausea or vomiting after eating, feeling too full after eating, bloating, and/or throat or stomach pain within the last 6 months

\*Other criteria apply. Talk to your doctor to learn more.

